A new biotech out of Dana-Far­ber wants to join the long non-cod­ing RNA par­ty, with help from Bob Langer

Biotechs fo­cus­ing on long non-cod­ing RNAs have pro­lif­er­at­ed in re­cent years, and an­oth­er new com­pa­ny an­nounced its launch ear­ly Tues­day.

Nex­tR­NA Ther­a­peu­tics came out of stealth with $56 mil­lion in fi­nanc­ing — $9.3 mil­lion from a seed fi­nanc­ing and $46.8 mil­lion from a Se­ries A — as it looks to join the in­creas­ing­ly crowd­ed “lncR­NA” biotech space. Found­ed in Jan­u­ary 2021, the com­pa­ny comes out of re­search from the Dana-Far­ber Can­cer In­sti­tute, and Ken­neth An­der­son and Bob Langer have lent their names as co-founders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER